Find an Alzheimer's clinical trial

If you are thinking about joining a trial

A listing here is a record that a study was registered. It is not a recommendation, and it does not mean the study is still recruiting or that anyone is eligible. Registry entries go stale.

Talk to the treating doctor first, then contact the study team listed on the official ClinicalTrials.gov record. The NIA's free referral line can help you look: 1-800-438-4380, weekdays, English and Spanish.

Search title, drug, condition or sponsor

Recruiting

Exact registry status

Phase

Intervention class

Study type

Country

Results per page

Clear filters Download all 7,816 as CSV

"Open to new participants" means the registry status is RECRUITING or NOT_YET_RECRUITING — 1,523 of the 7,816 records. That is what the sponsor last told the registry, which can be months out of date.
Location is by country. This pull of the registry records the countries a study runs in, not its individual sites, so we cannot filter by US state or city — and we are not going to guess one. To find the nearest site, open a trial's record below: the official page lists every location with its contact details.

Showing 7,101–7,125 of 7,816 matching trials · page 285 of 313, 25 per page.

Sorted by the date the registry record was last updated, newest first. This page never loads all 7,816 rows at once — use the CSV download if you want the whole file.

Registered Alzheimer's clinical trials. Every ID links to its official ClinicalTrials.gov record.
Trial	Phase	Status	Enrolled	Sponsor	Last updated
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) NCT00575055 Bapineuzumab 0.5 mg/kg; Placebo Control; Bapineuzumab 1.0 m/kg Runs in: United States · 186 sites	PHASE3 anti-amyloid-antibody	COMPLETED	1,121	JANSSEN Alzheimer Immunotherapy Research & Development, LLC INDUSTRY	2013-11-25
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease NCT00606476 Bapineuzumab (AAB-001) Runs in: United States · 29 sites	PHASE2 anti-amyloid-antibody	TERMINATED	194	JANSSEN Alzheimer Immunotherapy Research & Development, LLC INDUSTRY	2013-11-25
Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)) NCT01993628 Rey figure test; MRI Runs in: France · 1 site	NA other	UNKNOWN	80	University Hospital, Strasbourg, France OTHER	2013-11-25
Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients NCT00165750 DONEPEZIL HYDROCHLORIDE Runs in: South Korea · 1 site	PHASE4 symptomatic-cholinergic	TERMINATED	40	Eisai Korea Inc. INDUSTRY	2013-11-20
Study Evaluating Bapineuzumab In Alzheimer Disease Subjects NCT00663026 bapineuzumab; bapineuzumab; placebo Runs in: United States · 17 sites	PHASE2 anti-amyloid-antibody	COMPLETED	79	Pfizer INDUSTRY	2013-11-15
A Comparison of Two Standard Therapies in the Management of Dementia With Agitation NCT00208819 risperidone; quetiapine; olanzapine; divalproex Runs in: United States · 1 site	PHASE4 other	COMPLETED	50	Emory University OTHER	2013-11-13
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type NCT00036114 aripiprazole Runs in: United States · 41 sites	PHASE3 other	COMPLETED	—	Otsuka Pharmaceutical Development & Commercialization, Inc. INDUSTRY	2013-11-11
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type NCT00041678 aripiprazole Runs in: United States · 6 sites	PHASE3 other	COMPLETED	—	Otsuka Pharmaceutical Development & Commercialization, Inc. INDUSTRY	2013-11-11
Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia NCT00095719 Aripiprazole; Placebo Runs in: United States · 14 sites	PHASE3 other	COMPLETED	125	Otsuka Pharmaceutical Development & Commercialization, Inc. INDUSTRY	2013-11-11
Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions NCT01209156 [18F] PBR111 Runs in: United States · 1 site	PHASE1 other	COMPLETED	11	Institute for Neurodegenerative Disorders OTHER	2013-11-11
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC NCT01268020 [18F]-FMH3 Runs in: United States · 1 site	EARLY_PHASE1 other	COMPLETED	5	Institute for Neurodegenerative Disorders OTHER	2013-11-11
Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A NCT01568086 Runs in: Austria · 2 sites	NA other	TERMINATED	16	Affiris AG INDUSTRY	2013-11-06
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease NCT00663936 T-817MA; Placebo Runs in: Canada; United States · 35 sites	PHASE2 other	COMPLETED	373	FUJIFILM Toyama Chemical Co., Ltd. INDUSTRY	2013-11-05
Safety Study of Intranasal Oxytocin in Frontotemporal Dementia NCT01386333 oxytocin; Saline Nasal Mist Runs in: Canada · 1 site	PHASE1 other	COMPLETED	23	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's OTHER	2013-11-04
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type NCT00153010 NS 2330 (Tesofensine) Runs in: Canada; United States · 87 sites	PHASE2 other	COMPLETED	430	Boehringer Ingelheim INDUSTRY	2013-10-29
Internet App to Self-Manage Occasional Low Back Pain NCT01950091 FitBack on-line intervention; Alternative Website Control	NA other	COMPLETED	606	Oregon Center for Applied Science, Inc. INDUSTRY	2013-10-23
Efficiency of an Educational Program for Informal Caregivers of Hospitalized, Dependent Patients: Cluster Randomised Trial NCT01965392 Health education intervention	NA other	COMPLETED	151	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal OTHER	2013-10-18
Alzheimer's Family Research NCT00878059 Runs in: United States · 1 site	NA other	COMPLETED	165	University of California, San Francisco OTHER	2013-10-16
The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia NCT01363648 choline alfoscerate; placebo (for choline alphoscerate) Runs in: South Korea · 1 site	PHASE4 other	COMPLETED	222	Seoul National University Hospital OTHER	2013-10-14
Social Cognition in Ageing and in Frontotemporal Lobar Degeneration NCT01962064 Cognitive assessment; Brain imaging examination MRI Runs in: France · 1 site	NA other	UNKNOWN	80	University Hospital, Caen OTHER	2013-10-14
Music Therapy to Promote Emotion and Cognition for Dementia NCT01958983 Music Therapy Group Session Runs in: Taiwan · 1 site	NA other	UNKNOWN	30	Chang Gung Memorial Hospital OTHER	2013-10-09
A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein). NCT00978536 Cognitive impairment of multiple sclerosis Runs in: France · 1 site	NA other	TERMINATED	29	Nantes University Hospital OTHER	2013-09-30
Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies NCT00855686 Memantine; Placebo Runs in: Germany · 1 site	PHASE4 symptomatic-cholinergic	COMPLETED	199	H. Lundbeck A/S INDUSTRY	2013-09-20
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease NCT00679627 Galantamine; Placebo Runs in: Czechia; Estonia; France; Germany; Greece; Latvia; Lithua... · 95 sites	PHASE3 symptomatic-cholinergic	TERMINATED	2,051	Janssen Research & Development, LLC INDUSTRY	2013-09-19
A Study of Florbetapir (18F) in Japanese Healthy Volunteers NCT01660815 florbetapir (18F) Runs in: Japan · 1 site	PHASE1 other	COMPLETED	7	Avid Radiopharmaceuticals INDUSTRY	2013-09-19

This table is wider than a phone screen — swipe it sideways to see the rest.

Where these trials come from

Registry: ClinicalTrials.gov, pulled through their public API (v2)
Trials in the file: 7,816
Source file: trials.csv (3.8 MB, 7816 rows)
Basis: Measured These are registry records as submitted by each study's sponsor.

What could make this misleading

Sponsors enter their own data and do not always keep it current, so "recruiting" can be out of date by months or years. Enrollment figures may be targets rather than actual numbers; the downloaded file says which for each trial. Trials that were never registered do not appear at all, and the intervention class is this project's own grouping, not the registry's.

Always check the official record before acting on anything here. This is a summary, not medical advice.

From the research library

The highest-scoring studies we hold on this subject, each summarised in plain English. Scores are alzhub's usefulness score, not a verdict on the science.

Clinical trials

MINocyclinE to Reduce inflammation and blood-brain barrier leakage in small Vessel diseAse (MINERVA): A phase II, randomized, double-blind, placebo-controlled experimental medicine trial Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024 · score 88/100
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial The Lancet. Neurology, 2026 · score 86/100
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial Lancet (London, England), 2021 · score 86/100
Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease Journal of Alzheimer's disease : JAD, 2026 · score 86/100
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial EBioMedicine, 2024 · score 85/100

All 162 studies on Clinical trials →